Group 1 - Two companies terminated their IPO applications last week, both from the Shenzhen Stock Exchange: Guangdong Zhengyang Sensor Technology Co., Ltd. and Guizhou Duocai New Media Co., Ltd. [1] - Wuhan Heyuan Biotechnology Co., Ltd. became the first company to pass the IPO review under the new fifth standard of the Sci-Tech Innovation Board, after a wait of over two years [2][3] - Shenzhen Beixin Life Technology Co., Ltd. also passed the IPO review on July 18, 2023, after being in the queue for over two years [2][3] Group 2 - Guizhou Duocai New Media faced a single business risk, as its IPTV business accounted for over 99% of its revenue from 2019 to the first half of 2022 [4][5] - The company failed to submit its registration after 28 months post-approval, leading to the termination of its IPO application [4] - Guangdong Zhengyang Technology's cash dividend policy raised concerns, with a cumulative dividend payout of 83% of its net profit from 2020 to 2022, which is considered excessive [5][6] Group 3 - The new policies introduced on June 18, 2023, aimed to support high-quality, unprofitable tech companies in going public, including the reintroduction of the fifth standard for the Sci-Tech Innovation Board [2] - The review process for companies applying under the fifth standard has seen new developments, with three other companies still in the queue: Harbin Sizherui Intelligent Medical Equipment Co., Ltd., Shanghai Hengrun Da Biological Technology Co., Ltd., and Guangzhou Bibete Pharmaceutical Co., Ltd. [3]

Core Viewpoint - The medical equipment procurement amount in terminal hospitals has significantly increased in the first four months of this year, indicating a rapid recovery in the industry, with companies like Kaili Medical expressing confidence in returning to a growth trend [1][2]. Industry Summary - The total budget for medical equipment in Guizhou Province exceeds 578 million, and Hebei Province has made a one-time procurement of 79 ultrasound devices, indicating a reshaping of the domestic medical equipment market [1]. - The shift from "following" to "leading" in various segments by Chinese medical equipment manufacturers is becoming more pronounced [1]. - The procurement policies are expected to lead to a significant increase in the volume of equipment purchased, with a three-year cycle for equipment updates anticipated to boost sales [2]. Company Summary - Kaili Medical, which started with ultrasound equipment and expanded into endoscopy, is now a leading domestic player in soft endoscopes, with market share second only to Olympus and Fujifilm [2]. - In Q1 2024, Kaili Medical reported revenue of 430 million and a net profit of 8.07 million, both showing a decline, but there are signs of recovery with procurement activities picking up [2][3]. - The company has seen a significant increase in successful bids, with expectations for a "low first half, high second half" performance in 2024 [3]. - The recent collective procurement results in Hainan Province showed a budget of 190 million for 200 ultrasound devices, with a savings rate exceeding 37%, indicating a trend towards cost-effective procurement [3]. - Kaili Medical's dual business model of "ultrasound + endoscopy" is now stable, with optimistic growth projections for new business areas like minimally invasive surgery and cardiovascular intervention [5]. - The company has invested heavily in R&D, with 473 million allocated in 2024, representing 23.48% of revenue, and a 23.7% increase in R&D expenses in Q1 2025 [7].